Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HU6 PK and Safety in Overweight Participants
NCT07170189Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Oct 2025
- Primary completion
- Dec 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HU6 in obesity (5 arms), sponsored by Rivus Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration at 28 days and Safety and Tolerability at 28 days. Started Oct 2025; status: completed.
02
Drugs
HU6
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07170189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170189.